-
HIV drug resistance and the impact of antiretroviral therapy initiated at different stages among AIDS patiens
- YUAN Yuan, SI Heng, LIU Hongwei, LIU Chunhua, WANG Zhe, RUAN Yuhua, XING Hui
-
JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES). 2016, 54(9):
77-81.
doi:10.6040/j.issn.1671-7554.0.2016.005
-
Abstract
(
1113 )
PDF (1534KB)
(
238
)
Save
-
References |
Related Articles |
Metrics
Objective To compare the impact of antiretroviral therapy initiated at different stages on drug resistance among AIDS patients. Methods AIDS patients treated with first-line HAART for 6 months in Henan Province were investigated with cross-sectional survey and blood samples were collected. According to the level of baseline immunology, the patients were divided into 3 groups: early treatment group(n=132, CD4+T cell counts ≥ 350 cell/mm3), conventional treatment group(n=200, 200 cell/mm3 < CD4+T cell counts < 350 cell/mm3)and delayed treatment group(n=329, CD4+T cell counts ≤ 200 cell/mm3). The factors associated with the development of HIV-1 drug resistance were analyzed with multivariate logistic regression. Results A total of 661 patients were investigated. The total prevalence of HIV-1 drug resistance was 34.3%(227/661). The prevalence of drug resistance in the early treatment group, conventional treatment group and delayed treatment group was 21.2%(28/132), 35.5%(71/200)and 38.9%(128/329), respectively. Multivariate logistic regression analysis showed that the protective factors associated with the development of drug resistance included earlier treatment(OR=0.31, 95%CI 0.19-0.51, P<0.001), high compliance(OR=0.48, 95%CI 0.30-0.78, P=0.003)and initiation of ART with 3TC(OR=0.20, 95%CI 0.20- 山 东 大 学 学 报 (医 学 版)54卷9期 -袁源,等.不同时期抗病毒治疗对艾滋病患者耐药产生的影响分析 \=-0.40, P<0.001), while long-duration of treatment(OR=1.90, 95%CI 1.22-2.95, P=0.004 3)was the risk factor. Conclusion Early initiation of antiretroviral therapy for AIDS patients receiving HAART could reduce the emergence of the drug resistant strains and acquire good effect.